Will Other Insurers Follow Palmetto's Lead in Covering Genomic Health's Colon Cancer Oncotype DX?
October 05, 2011
Will Other Insurers Follow Palmetto's Lead in Covering Genomic Health's Colon Cancer Oncotype DX?
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Medicare to Cover Genomic Health's Oncotype DX Breast Cancer Test for DCIS
May 13, 2013 / GenomeWeb Daily News - Data Supports Oncotype DX for Predicting Recurrence in Node-Positive Cancers, Guiding Radiation Therapy
March 13, 2013 / Pharmacogenomics Reporter - Palmetto Loses Appeal to Remain JE CMS Contractor, but May Continue Running MolDx
January 30, 2013 / Pharmacogenomics Reporter - Palmetto's Loss of Jurisdiction E Medicare Contract Raises Questions About Fate of MolDx Program
October 17, 2012 / Pharmacogenomics Reporter - New Firm MetaDiagnostic Moves in to Help Dx Developers, Payors as PBMs Shift from Personalized Rx
August 29, 2012 / Pharmacogenomics Reporter